NASDAQ:XNCR

Xencor - XNCR Stock Forecast, Price & News

$28.17

-0.37 (-1.30%)

(As of 11/28/2022 12:00 AM ET)

Add

Compare

Today's Range: $27.96
▼
$28.75
50-Day Range: $24.62
▼
$30.51
52-Week Range: $19.35
▼
$42.30

Volume: 329,870 shs
Average Volume: 344,843 shs
Market Capitalization: $1.69 billion

P/E Ratio: 58.69
Dividend Yield: N/A
Price Target: $48.89

Xencor MarketRank™ Forecast

Analyst Rating: Buy
3.11 Rating Score
Upside/Downside: 73.5% Upside
$48.89 Price Target
Short Interest: Bearish
6.84% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.24
Upright™ Environmental Score
News Sentiment: 0.80
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.65) to ($2.69) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

508th out of 1,040 stocks

Pharmaceutical Preparations Industry

242nd out of 509 stocks

3.6

Analyst's Opinion

Consensus Rating
Xencor has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.89, Xencor has a forecasted upside of 73.5% from its current price of $28.17.
Amount of Analyst Coverage
Xencor has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
6.84% of the outstanding shares of Xencor have been sold short.
Short Interest Ratio / Days to Cover
Xencor has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Xencor has recently increased by 1.74%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Xencor does not currently pay a dividend.
Dividend Growth
Xencor does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Xencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Xencor is -2.24.

2.7

News and Social Media Coverage

News Sentiment
Xencor has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Xencor this week, compared to 2 articles on an average week.
Search Interest
9 people have searched for XNCR on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xencor insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.23% of the stock of Xencor is held by insiders.
Percentage Held by Institutions
99.28% of the stock of Xencor is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Xencor are expected to decrease in the coming year, from ($1.65) to ($2.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xencor is 58.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.25.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xencor is 58.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.75.
Price to Book Value per Share Ratio
Xencor has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Xencor (NASDAQ:XNCR) Stock

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Stock News Headlines

November 25, 2022 | finance.yahoo.com

Xencor (XNCR) Upgraded to Buy: Here's What You Should Know

November 10, 2022 | finance.yahoo.com

Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting

November 28, 2022 | Legacy Research (Affiliate) (Ad)

THE BEST BLACK FRIDAY DEAL YET

This Black Friday, you can save 95% off of a 1-year membership to Brad Thomas’s Intelligent Income Investor. This service is geared toward helping you collect the safest dividend income in the market. It all starts with Brad’s “SWAN” portfolio, of the 10 best companies to own through any market.

November 10, 2022 | finance.yahoo.com

Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?

November 6, 2022 | msn.com

Xencor Earnings Preview

November 3, 2022 | finance.yahoo.com

Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting

November 1, 2022 | finance.yahoo.com

Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022

October 20, 2022 | nasdaq.com

Peek Under The Hood: SLYG Has 37% Upside - Nasdaq

November 28, 2022 | Legacy Research (Affiliate) (Ad)

See how to make money instead of spending it on Black Friday with this offer

Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Even the world’s richest billionaires are investing in the tiny company behind it. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday.

October 20, 2022 | finance.yahoo.com

SpikImm, a Biotechnology Company Founded by Truffle Capital Under License from the Institut Pasteur, Announces that the Clinical Trials for SPK001, its Monoclonal Antibody Against SARS-COV-2, Have Begun - Yahoo Finance

October 19, 2022 | finance.yahoo.com

24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight - Yahoo Finance

October 17, 2022 | businesswire.com

Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022 - Business Wire

October 15, 2022 | money.usnews.com

Xencor Inc

October 14, 2022 | finance.yahoo.com

Xencor, Inc. (NASDAQ:XNCR) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance

October 14, 2022 | finance.yahoo.com

Xencor, Inc. (NASDAQ:XNCR) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

October 10, 2022 | benzinga.com

Gastrointestinal Stromal Tumors Therapeutics Market Size to Grow by USD 1.08 Bn, Growing Geriatric Popula - Benzinga

October 7, 2022 | nasdaq.com

‘Take Opportunities on Days Like Today’: Mary Callahan Erdoes Says Now Could Be the Best Time to Invest. Here Are 3 Stocks to Consider - Nasdaq

October 7, 2022 | finance.yahoo.com

‘Take Opportunities on Days Like Today’: Mary Callahan Erdoes Says Now Could Be the Best Time to Invest. Here Are 3 Stocks to Consider - Yahoo Finance

October 5, 2022 | finance.yahoo.com

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting

October 5, 2022 | finance.yahoo.com

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting

October 5, 2022 | businesswire.com

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting - Business Wire

October 1, 2022 | reuters.com

XNCR.A - Xencor Inc | Stock Price & Latest News | Reuters

September 29, 2022 | finance.yahoo.com

Bispecific Antibodies for Cancer Market Size to Grow by USD 396.56 million, Emerging Bispecific Antibody Generation Platforms to be Key Trend - Technavio - Yahoo Finance

September 28, 2022 | reuters.com

XNCR.OQ - Xencor Inc | Stock Price & Latest News | Reuters

September 19, 2022 | nasdaq.com

Is Xencor, Inc.'s (NASDAQ:XNCR) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Nasdaq

September 19, 2022 | nasdaq.com

Is Xencor, Inc.'s (NASDAQ:XNCR) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

September 9, 2022 | businesswire.com

Xencor Appoints Nancy Valente, M.D., to Board of Directors - Business Wire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Company Calendar

Last Earnings: 11/08/2021
Today: 11/28/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/22/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XNCR
CUSIP: N/A
CIK: 1326732
Web: www.xencor.com
Phone: (626) 305-5900
Fax: 626-305-0350
Employees: 254
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $48.89
High Stock Price Forecast: $60.00
Low Stock Price Forecast: $36.00
Forecasted Upside/Downside: +73.5%
Consensus Rating: Buy
Rating Score (0-4): 3.11
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.48
Trailing P/E Ratio: 58.69
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $82.63 million
Net Margins: 10.07%
Pretax Margin: 10.44%
Return on Equity: 4.04%
Return on Assets: 3.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.42
Quick Ratio: 7.42

Sales & Book Value

Annual Sales: $275.11 million
Price / Sales: 6.14
Cash Flow: $1.59 per share
Price / Cash Flow: 17.72
Book Value: $12.54 per share
Price / Book: 2.25

Miscellaneous

Outstanding Shares: 59,924,000
Free Float: 57,389,000
Market Cap: $1.69 billion
Optionable: Optionable
Beta: 0.62

Key Executives

Dr. Bassil I. Dahiyat Ph.D. (Age 52)
Co-Founder, CEO, Pres & Director
Comp: $1.08M

Mr. John J. Kuch (Age 63)
Sr. VP & CFO
Comp: $648.03k

Dr. John R. Desjarlais (Age 58)
Sr. VP of Research & Chief Scientific Officer
Comp: $725.03k

Ms. Celia E. Eckert J.D. (Age 49)
Sr. VP, Gen. Counsel & Corp. Sec.
Comp: $600.93k

Dr. Allen S. Yang M.D. (Age 54)
Ph.D., Sr. VP & Chief Medical Officer
Comp: $748.13k

Mr. Charles Liles
Associate Director and Head of Corp. Communications & Investor Relations

Ms. Jennifer Sandoz
VP of HR

Dr. Jeremy Grunstein Ph.D.
Sr. VP of Bus. Devel.

Mr. Kirk Rosemark RAC (Age 57)
Sr. VP of Regulatory Affairs & Quality Assurance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XNCR Stock - Frequently Asked Questions

Should I buy or sell Xencor stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings or view top-rated stocks.
What is Xencor's stock price forecast for 2023?: 9 Wall Street research analysts have issued 12-month price targets for Xencor's shares. Their XNCR share price forecasts range from $36.00 to $60.00. On average, they predict the company's stock price to reach $48.89 in the next year. This suggests a possible upside of 71.3% from the stock's current price.
View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts.
How have XNCR shares performed in 2022?: Xencor's stock was trading at $40.12 at the start of the year. Since then, XNCR shares have decreased by 28.9% and is now trading at $28.54.
View the best growth stocks for 2022 here.
When is Xencor's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our XNCR earnings forecast.
How were Xencor's earnings last quarter?: Xencor, Inc. (NASDAQ:XNCR) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.06. The biopharmaceutical company earned $19.68 million during the quarter, compared to analysts' expectations of $17.63 million. Xencor had a trailing twelve-month return on equity of 4.04% and a net margin of 10.07%. During the same period in the previous year, the business earned ($0.22) EPS.
What is Bassil I. Dahiyat's approval rating as Xencor's CEO?: 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).
What is Xencor's stock symbol?: Xencor trades on the NASDAQ under the ticker symbol "XNCR."
Who are Xencor's major shareholders?: Xencor's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.70%), Vanguard Group Inc. (10.95%), Primecap Management Co. CA (9.50%), State Street Corp (5.43%), Price T Rowe Associates Inc. MD (5.36%) and Dimensional Fund Advisors LP (1.95%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends.
How do I buy shares of Xencor?: Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Xencor's stock price today?: One share of XNCR stock can currently be purchased for approximately $28.54.
How much money does Xencor make?: Xencor (NASDAQ:XNCR) has a market capitalization of $1.71 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $0.48 on an earnings per share basis.
How many employees does Xencor have?: The company employs 254 workers across the globe.
How can I contact Xencor?: Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 11/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Xencor - XNCR Stock Forecast, Price & News

Xencor MarketRank™ Forecast

Overall MarketRank™